Baxter added to US Conviction List at Goldman Sachs

Goldman Sachs analysts added Baxter (BAX) to the firm’s US Conviction List as part of its monthly update. The firm expects a turnaround in shares after a long period of underperformance catalyzed by the company’s “stable,” mid-single-digit, revenue growth, “significant” operating margin expansion and free cash flow growth. Goldman has a Buy rating on Baxter with a $42 price target